Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy

Whether to continue oral anticoagulant therapy beyond 6 months after an "unprovoked" venous thromboembolism is controversial. We sought to determine clinical predictors to identify patients who are at low risk of recurrent venous thromboembolism who could safely discontinue oral anticoagul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Canadian Medical Association journal 2008-08, Vol.179 (5), p.417-426
Hauptverfasser:	Rodger, Marc A., MD MSc, Kahn, Susan R., MD MSc, Wells, Philip S., MD MSc, Anderson, David A., MD, Chagnon, Isabelle, MD, Le Gal, Gregoire, MD PhD, Solymoss, Susan, MD, Crowther, Mark, MD, Perrier, Arnaud, MD, White, Richard, MD, Vickars, Linda, MD, Ramsay, Tim, PhD MSc, Betancourt, Marisol T., MD MSc, Kovacs, Michael J., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Aged Aged, 80 and over Anticardiolipin antibodies Anticoagulants Anticoagulants - administration & dosage Blood coagulation factors Contraindications Drug therapy Enzyme-linked immunosorbent assay Female Follow-Up Studies Human health and pathology Humans Immunoglobulins Life Sciences Lupus Male Medical research Medicine, Experimental Middle Aged Obesity Observer Variation Operating Room Nursing Pharmaceutical industry Pressure Ulcer Prospective Studies Pulmonary embolism Recurrence Risk Factors Shipping industry Surgical Equipment Thromboembolism Thrombosis Time Factors Treatment Outcome Vein & artery diseases Venous Thromboembolism Venous Thromboembolism - diagnosis Venous Thromboembolism - drug therapy Warfarin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!